Ninety Days of Preoperative Endocrine Therapy Informs Patientand Physician Preference for Radiation Therapy: Primary Resultsfrom the Preoperative Window of Endocrine Therapy to InformRadiation Therapy Decisions (POWER) Trial Por Kati Ninety Days of Preoperative Endocrine Therapy Informs Patientand Physician Preference for Radiation Therapy: Primary Resultsfrom the Preoperative Window of Endocrine Therapy to InformRadiation Therapy Decisions (POWER) Trial Read More »
Postmastectomy Radiation Therapy: An ASTRO-ASCO-SSOClinical Practice Guideline Por Kati Postmastectomy Radiation Therapy: An ASTRO-ASCO-SSOClinical Practice Guideline Read More »
Real-world progression-free survival of CDK4/6 inhibitors plus anaromatase inhibitor in HR-positive/HER2-negative metastatic breast cancerin United States routine clinical practice Por Adson Machado Real-world progression-free survival of CDK4/6 inhibitors plus anaromatase inhibitor in HR-positive/HER2-negative metastatic breast cancerin United States routine clinical practice Read More »
Real‑World Application of Alliance ACOSOG Z11102: HowMany Patients Can be Spared Mastectomy? Por Adson Machado Real‑World Application of Alliance ACOSOG Z11102: HowMany Patients Can be Spared Mastectomy? Read More »
Artificial Intelligence in Symptomatic Carotid Plaque Detection: A Narrative Review Por Adson Machado Artificial Intelligence in Symptomatic Carotid Plaque Detection: A Narrative Review Read More »
The association between young age atmetastatic breast cancer diagnosis andoverall survival in the EMBRACE study Por Kati The association between young age atmetastatic breast cancer diagnosis andoverall survival in the EMBRACE study Read More »
GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity Por Kati GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity Read More »
Impact of Anthracyclines in Genomic High Risk, Node-Negative, HR-Positive/HER2-Negative Breast Cancer Por Adson Machado Impact of Anthracyclines in Genomic High Risk, Node-Negative, HR-Positive/HER2-Negative Breast Cancer Read More »
Iodine Seed−Marking Protocol for Response-Guided Axillary TreatmentAfter Systemic Therapy for Node-Positive Breast Cancer Por Adson Machado Iodine Seed−Marking Protocol for Response-Guided Axillary TreatmentAfter Systemic Therapy for Node-Positive Breast Cancer Read More »
Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay Por Adson Machado Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay Read More »
Biology is Queen: The Oncotype DX 21‑Gene Recurrence ScoreHas Stronger Prognostic Ability than Lymph Node Burdenfor Patients with Breast Cancer Por Adson Machado Biology is Queen: The Oncotype DX 21‑Gene Recurrence ScoreHas Stronger Prognostic Ability than Lymph Node Burdenfor Patients with Breast Cancer Read More »
Patritumab deruxtecan in HR+HER2−advanced breast cancer: a phase 2 trial Por Kati Patritumab deruxtecan in HR+HER2−advanced breast cancer: a phase 2 trial Read More »
